CA2692861A1 - Variants d'epissage de cd44 dans des maladies neurodegeneratives - Google Patents
Variants d'epissage de cd44 dans des maladies neurodegeneratives Download PDFInfo
- Publication number
- CA2692861A1 CA2692861A1 CA 2692861 CA2692861A CA2692861A1 CA 2692861 A1 CA2692861 A1 CA 2692861A1 CA 2692861 CA2692861 CA 2692861 CA 2692861 A CA2692861 A CA 2692861A CA 2692861 A1 CA2692861 A1 CA 2692861A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- homologous
- amino acid
- coordinates
- contiguous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000004770 neurodegeneration Effects 0.000 title claims abstract description 63
- 208000015122 neurodegenerative disease Diseases 0.000 title claims abstract description 63
- 101150017002 CD44 gene Proteins 0.000 title description 15
- 239000002773 nucleotide Substances 0.000 claims abstract description 252
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 251
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 181
- 150000001413 amino acids Chemical class 0.000 claims abstract description 171
- 230000014509 gene expression Effects 0.000 claims abstract description 156
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 130
- 238000000034 method Methods 0.000 claims abstract description 100
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 86
- 229920001184 polypeptide Polymers 0.000 claims abstract description 76
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 70
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 67
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 67
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 40
- 230000000694 effects Effects 0.000 claims abstract description 24
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 22
- 229920002477 rna polymer Polymers 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 102000040430 polynucleotide Human genes 0.000 claims description 78
- 108091033319 polynucleotide Proteins 0.000 claims description 78
- 239000002157 polynucleotide Substances 0.000 claims description 78
- 208000024827 Alzheimer disease Diseases 0.000 claims description 71
- 108020004459 Small interfering RNA Proteins 0.000 claims description 57
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 50
- 239000004055 small Interfering RNA Substances 0.000 claims description 48
- 108091034117 Oligonucleotide Proteins 0.000 claims description 46
- 239000012472 biological sample Substances 0.000 claims description 43
- 208000018737 Parkinson disease Diseases 0.000 claims description 33
- 208000005264 motor neuron disease Diseases 0.000 claims description 33
- 108020004414 DNA Proteins 0.000 claims description 30
- 102000053602 DNA Human genes 0.000 claims description 30
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims description 29
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims description 29
- 201000010901 lateral sclerosis Diseases 0.000 claims description 29
- 238000003752 polymerase chain reaction Methods 0.000 claims description 28
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 28
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims description 21
- 230000000295 complement effect Effects 0.000 claims description 16
- 230000037361 pathway Effects 0.000 claims description 13
- 238000003753 real-time PCR Methods 0.000 claims description 13
- 239000002299 complementary DNA Substances 0.000 claims description 11
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 claims description 10
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 claims description 10
- 238000009396 hybridization Methods 0.000 claims description 7
- 238000003364 immunohistochemistry Methods 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 6
- 238000000636 Northern blotting Methods 0.000 claims description 5
- 239000013060 biological fluid Substances 0.000 claims description 5
- 150000003384 small molecules Chemical group 0.000 claims description 5
- 238000001262 western blot Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 238000003365 immunocytochemistry Methods 0.000 claims description 3
- 238000012340 reverse transcriptase PCR Methods 0.000 claims description 3
- 239000003184 complementary RNA Substances 0.000 claims description 2
- 102100032912 CD44 antigen Human genes 0.000 claims 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 description 101
- 210000004027 cell Anatomy 0.000 description 86
- 108700024394 Exon Proteins 0.000 description 85
- 102000004169 proteins and genes Human genes 0.000 description 83
- 239000000047 product Substances 0.000 description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
- 108091026890 Coding region Proteins 0.000 description 32
- 238000006243 chemical reaction Methods 0.000 description 30
- 201000010099 disease Diseases 0.000 description 28
- 239000013615 primer Substances 0.000 description 26
- 210000002569 neuron Anatomy 0.000 description 23
- 210000001519 tissue Anatomy 0.000 description 21
- 241000282414 Homo sapiens Species 0.000 description 17
- 239000000523 sample Substances 0.000 description 17
- 102000001708 Protein Isoforms Human genes 0.000 description 15
- 108010029485 Protein Isoforms Proteins 0.000 description 15
- 238000010240 RT-PCR analysis Methods 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 210000001130 astrocyte Anatomy 0.000 description 14
- 210000004556 brain Anatomy 0.000 description 14
- 108010085238 Actins Proteins 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 13
- 238000010186 staining Methods 0.000 description 12
- 230000002441 reversible effect Effects 0.000 description 11
- 102000007469 Actins Human genes 0.000 description 10
- 102100034343 Integrase Human genes 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 10
- 238000010839 reverse transcription Methods 0.000 description 10
- 238000011282 treatment Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 230000000692 anti-sense effect Effects 0.000 description 9
- 210000001320 hippocampus Anatomy 0.000 description 9
- 210000002161 motor neuron Anatomy 0.000 description 9
- 230000001537 neural effect Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 241000699660 Mus musculus Species 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 239000011543 agarose gel Substances 0.000 description 7
- 230000000971 hippocampal effect Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 6
- 208000037259 Amyloid Plaque Diseases 0.000 description 6
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 239000000074 antisense oligonucleotide Substances 0.000 description 6
- 238000012230 antisense oligonucleotides Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229920002674 hyaluronan Polymers 0.000 description 6
- 229940014041 hyaluronate Drugs 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000013139 quantization Methods 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 102000003886 Glycoproteins Human genes 0.000 description 5
- 108090000288 Glycoproteins Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 210000000337 motor cortex Anatomy 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000000750 progressive effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000000278 spinal cord Anatomy 0.000 description 5
- 230000003827 upregulation Effects 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 4
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 4
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
- 102000002068 Glycopeptides Human genes 0.000 description 4
- 108010015899 Glycopeptides Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000004900 autophagic degradation Effects 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000015556 catabolic process Effects 0.000 description 4
- 230000030570 cellular localization Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- -1 for example Chemical class 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 101710197633 Actin-1 Proteins 0.000 description 3
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 108010092694 L-Selectin Proteins 0.000 description 3
- 102100023231 Lysosomal alpha-mannosidase Human genes 0.000 description 3
- 239000013614 RNA sample Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 201000002491 encephalomyelitis Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000030279 gene silencing Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 210000004885 white matter Anatomy 0.000 description 3
- 102000016284 Aggrecans Human genes 0.000 description 2
- 108010067219 Aggrecans Proteins 0.000 description 2
- 102000004072 Beclin-1 Human genes 0.000 description 2
- 108090000524 Beclin-1 Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 108010029697 CD40 Ligand Proteins 0.000 description 2
- 102100032937 CD40 ligand Human genes 0.000 description 2
- 102000005598 Chondroitin Sulfate Proteoglycans Human genes 0.000 description 2
- 108010059480 Chondroitin Sulfate Proteoglycans Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 101100059521 Homo sapiens CD44 gene Proteins 0.000 description 2
- 102000016551 L-selectin Human genes 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 101710135169 Lysosomal alpha-mannosidase Proteins 0.000 description 2
- 101100059523 Mus musculus Cd44 gene Proteins 0.000 description 2
- 206010028570 Myelopathy Diseases 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 108091093037 Peptide nucleic acid Proteins 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 102000012412 Presenilin-1 Human genes 0.000 description 2
- 102000012419 Presenilin-2 Human genes 0.000 description 2
- 108010036908 Presenilin-2 Proteins 0.000 description 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 2
- 241000219061 Rheum Species 0.000 description 2
- 206010044696 Tropical spastic paresis Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000007791 alzheimer disease like pathology Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000003140 astrocytic effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 230000002222 downregulating effect Effects 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 210000000274 microglia Anatomy 0.000 description 2
- 230000002025 microglial effect Effects 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 230000004960 subcellular localization Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 102400000967 Bradykinin Human genes 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 241001573498 Compacta Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000005599 HTLV-I Infections Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical group OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000980898 Homo sapiens Cell division cycle-associated protein 4 Proteins 0.000 description 1
- 101000578353 Homo sapiens Nodal modulator 2 Proteins 0.000 description 1
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 description 1
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 1
- 102000010836 Lymphocyte Homing Receptors Human genes 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000027382 Mental deterioration Diseases 0.000 description 1
- 206010027374 Mental impairment Diseases 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010056677 Nerve degeneration Diseases 0.000 description 1
- 102100027967 Nodal modulator 2 Human genes 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010033885 Paraparesis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000016202 Proteolipids Human genes 0.000 description 1
- 108010010974 Proteolipids Proteins 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000002548 Spastic Paraparesis Diseases 0.000 description 1
- 101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 102100021947 Survival motor neuron protein Human genes 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 101150052863 THY1 gene Proteins 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000005122 aminoalkylamino group Chemical group 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000011861 anti-inflammatory therapy Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000002886 autophagic effect Effects 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 208000025698 brain inflammatory disease Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000453 cell autonomous effect Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000008619 cell matrix interaction Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 description 1
- 230000009266 disease activity Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 102000044493 human CDCA4 Human genes 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000013388 immunohistochemistry analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000126 in silico method Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000007154 intracellular accumulation Effects 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 108010028930 invariant chain Proteins 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 210000002241 neurite Anatomy 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 210000001026 paleocortex Anatomy 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical group 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000013823 prenylation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 210000005238 principal cell Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009719 regenerative response Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 102000015340 serglycin Human genes 0.000 description 1
- 108010050065 serglycin Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007838 tissue remodeling Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US92970607P | 2007-07-10 | 2007-07-10 | |
| US60/929,706 | 2007-07-10 | ||
| PCT/IB2008/052786 WO2009007934A2 (fr) | 2007-07-10 | 2008-07-10 | Variants d'épissage de cd44 dans des maladies neurodégénératives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2692861A1 true CA2692861A1 (fr) | 2009-01-15 |
Family
ID=40229192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2692861 Abandoned CA2692861A1 (fr) | 2007-07-10 | 2008-07-10 | Variants d'epissage de cd44 dans des maladies neurodegeneratives |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9018180B2 (fr) |
| EP (1) | EP2167692B1 (fr) |
| JP (1) | JP2010532989A (fr) |
| KR (1) | KR20100044793A (fr) |
| CN (1) | CN101821407B (fr) |
| AU (1) | AU2008273713B2 (fr) |
| BR (1) | BRPI0814685A2 (fr) |
| CA (1) | CA2692861A1 (fr) |
| EA (1) | EA201070108A1 (fr) |
| ES (1) | ES2423182T3 (fr) |
| HK (1) | HK1145856A1 (fr) |
| IL (1) | IL203130A (fr) |
| MX (1) | MX2010000236A (fr) |
| NZ (1) | NZ582390A (fr) |
| WO (1) | WO2009007934A2 (fr) |
| ZA (1) | ZA201000083B (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0821227A2 (pt) | 2007-12-19 | 2015-06-16 | Cancer Rec Tech Ltd | Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos |
| DK2531502T3 (da) | 2010-02-01 | 2014-05-19 | Cancer Rec Tech Ltd | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea og associerede forbindelser og ders anvendelse i terapi |
| JP5960793B2 (ja) * | 2011-03-24 | 2016-08-02 | ニューリム ファーマシューティカルズ（１９９１）リミテッド | 神経保護ペプチド |
| US9399779B2 (en) * | 2011-06-08 | 2016-07-26 | The Corporation Of Mercer University | Alternative splicing constructs and methods of use |
| CN104277092B (zh) * | 2013-07-12 | 2017-10-31 | 天津医科大学 | 用于预防和/或治疗老年性痴呆的β片层阻断肽 |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| WO2016033774A1 (fr) | 2014-09-04 | 2016-03-10 | 天津医科大学 | Peptide neutralisant les feuillets beta destiné à la prévention et/ou au traitement de la maladie d'alzheimer |
| CN107815438A (zh) * | 2017-08-02 | 2018-03-20 | 清华大学 | 重组细胞、筛选l型钙通道调节剂的方法、试剂在制备药物中的用途和药物组合物 |
| AU2022272870A1 (en) | 2021-05-11 | 2023-11-02 | Neurim Pharmaceuticals (1991) Ltd. | Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990299A (en) | 1995-08-14 | 1999-11-23 | Icn Pharmaceuticals, Inc. | Control of CD44 gene expression for therapeutic use |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6150162A (en) | 1998-12-17 | 2000-11-21 | Isis Pharmaceuticals Inc. | Antisense modulation of CD44 expression |
| IL133647A0 (en) * | 1999-06-08 | 2001-04-30 | Yissum Res Dev Co | Novel cd44 variant |
| KR101215789B1 (ko) | 2000-03-30 | 2012-12-26 | 화이트헤드 인스티튜트 포 바이오메디칼 리서치 | Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체 |
| CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
| JP2004537282A (ja) | 2001-03-23 | 2004-12-16 | エージーワイ セラピューティクス | 脳腫瘍の処置及び可視化における生体分子標的の使用法 |
| EP1386004A4 (fr) * | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | Modulation de l'expression genique associee a la proliferation inflammatoire et a la croissance de neurites, par des procedes faisant intervenir l'acide nucleique |
| WO2002097044A2 (fr) | 2001-05-25 | 2002-12-05 | Thomas Jefferson University | Formes d'epissage alternatives de proteines servant de base pour modalites therapeutiques multiples |
| US7833779B2 (en) * | 2001-07-25 | 2010-11-16 | Jivan Biologies Inc. | Methods and systems for polynucleotide detection |
| EP1670943B1 (fr) * | 2003-09-30 | 2013-11-13 | Evotec International GmbH | Utilisation diagnostique et therapeutique d'une sulfotransferase pour la maladie d'alzheimer |
| DE602006019582D1 (de) * | 2005-06-16 | 2011-02-24 | Evotec Neurosciences Gmbh | Adarb2 proteine als diagnostische und therapeutische targets für neurodegenerative erkrankungen |
-
2008
- 2008-07-10 CA CA 2692861 patent/CA2692861A1/fr not_active Abandoned
- 2008-07-10 US US12/668,563 patent/US9018180B2/en active Active
- 2008-07-10 CN CN2008801049431A patent/CN101821407B/zh active Active
- 2008-07-10 JP JP2010515648A patent/JP2010532989A/ja active Pending
- 2008-07-10 EP EP08776569.9A patent/EP2167692B1/fr active Active
- 2008-07-10 ES ES08776569T patent/ES2423182T3/es active Active
- 2008-07-10 WO PCT/IB2008/052786 patent/WO2009007934A2/fr active Application Filing
- 2008-07-10 BR BRPI0814685A patent/BRPI0814685A2/pt not_active IP Right Cessation
- 2008-07-10 MX MX2010000236A patent/MX2010000236A/es active IP Right Grant
- 2008-07-10 NZ NZ582390A patent/NZ582390A/en not_active IP Right Cessation
- 2008-07-10 KR KR1020107001642A patent/KR20100044793A/ko not_active Application Discontinuation
- 2008-07-10 AU AU2008273713A patent/AU2008273713B2/en active Active
- 2008-07-10 EA EA201070108A patent/EA201070108A1/ru unknown
-
2010
- 2010-01-04 IL IL203130A patent/IL203130A/en not_active IP Right Cessation
- 2010-01-05 ZA ZA2010/00083A patent/ZA201000083B/en unknown
-
2011
- 2011-01-06 HK HK11100082.6A patent/HK1145856A1/xx unknown
-
2015
- 2015-03-27 US US14/671,281 patent/US9416166B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2167692A2 (fr) | 2010-03-31 |
| WO2009007934A2 (fr) | 2009-01-15 |
| AU2008273713A1 (en) | 2009-01-15 |
| US20110172286A1 (en) | 2011-07-14 |
| NZ582390A (en) | 2012-05-25 |
| CN101821407B (zh) | 2013-09-18 |
| AU2008273713B2 (en) | 2014-07-03 |
| US9416166B2 (en) | 2016-08-16 |
| KR20100044793A (ko) | 2010-04-30 |
| BRPI0814685A2 (pt) | 2019-09-24 |
| ES2423182T3 (es) | 2013-09-18 |
| JP2010532989A (ja) | 2010-10-21 |
| MX2010000236A (es) | 2010-06-02 |
| HK1145856A1 (en) | 2011-05-06 |
| CN101821407A (zh) | 2010-09-01 |
| IL203130A (en) | 2014-07-31 |
| WO2009007934A3 (fr) | 2009-05-07 |
| EA201070108A1 (ru) | 2010-06-30 |
| EP2167692B1 (fr) | 2013-05-22 |
| US9018180B2 (en) | 2015-04-28 |
| ZA201000083B (en) | 2011-03-30 |
| US20150266940A1 (en) | 2015-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9416166B2 (en) | CD44 splice variants in neurodegenerative diseases | |
| US20080038730A1 (en) | Diagnostic and Therapeutic Use of Kcnj6 for Alzheimer's Disease | |
| Kumamoto et al. | Hyperactivation of midbrain dopaminergic system in schizophrenia could be attributed to the down-regulation of dysbindin | |
| US20110033480A1 (en) | Methods and compositions involving nucleotide repeat disorders | |
| WO2013181618A2 (fr) | Méthodes pour traiter la maladie d'alzheimer à l'aide d'inhibiteurs d'apoe | |
| US20080051334A1 (en) | Diagnostic and Therapeutic Use of Kcnc1 for Neurodegenerative Diseases | |
| JP2008545402A (ja) | 神経変性疾患の診断及び治療ターゲットとしてのｋｃｎｎ３ | |
| JP2009529490A (ja) | ニューロンの可塑性および再生を増強するための組成物および方法 | |
| EP1776591B1 (fr) | Applications diagnostiques et therapeutiques d'une atpase de la membrane plasmique | |
| US20060259991A1 (en) | Diagnostic and therapeutic use of scn2b protein for neurodegeneraative diseases | |
| US8871443B2 (en) | Schizophrenia-related isoform of KCNH2 and development of antipsychotic drugs | |
| CA2590751A1 (fr) | Sequences polynucleotidiques et polypeptidiques participant au remodelage osseux | |
| EP3246407B1 (fr) | Marqueur 65b13 de cellules progénitrices de neurones gaba | |
| KR102601020B1 (ko) | 파골 세포 분화 조절용 조성물 및 이의 용도 | |
| EP2521919B1 (fr) | Méthode de diagnostic et de surveillance de la schizophrénie et des tauopathies | |
| EP1721008B1 (fr) | Utilisation diagnostique et therapeutique du gene et de la proteine mal2 pour les maladies neurodegenerescentes | |
| JP2006518199A (ja) | 神経変性疾患に対するｓｃｎ２ｂタンパク質の診断的かつ治療的使用 | |
| EP1735626A2 (fr) | Diagnostic et utilisation therapeutique de kcnc1 de maladies neurodegeneratives | |
| WO2013175469A1 (fr) | Compositions et procédés de traitement et de diagnostic de troubles neurodégénératifs | |
| WO2007101991A1 (fr) | Cible pour l'amélioration d'une fonction cognitive |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDC | Correction of dead application (reinstatement) | ||
| EEER | Examination request |
Effective date: 20130509 |
|
| FZDE | Dead |
Effective date: 20180605 |